Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

le market of millions of diabetic foot infections annually with a potential estimated half billion dollar market."

Benjamin Lipsky, M.D., Professor of Medicine, University of Washington School of Medicine and Chairman of the Infectious Disease Society of America (IDSA) Guidelines Committee on Diabetic Foot Infection, commented, "I think there is a clear need for a topical antimicrobial compound for treatment of mild diabetic foot infections. Why expose the entire body to the potential toxic and microbial-altering effects of systemic therapy when the infection is limited to a superficial wound? With the growing problem of resistance of microorganisms to antibiotics, new types of antimicrobial agents and novel routes of treatment that allow lower doses of these agents would be welcomed. There are currently very few topical antimicrobial compounds available, none of which has been specifically proved to be effective for diabetic foot infections."

Under the terms of the license agreement, MacroChem will pay Genaera an initial fee of $1 million through February 1, 2008. The deal terms also include payments of $7 million to Genaera upon the achievement of certain clinical and regulatory milestones through approval, sales-based milestones of up to $35 million, and 10% royalty payments on net sales. In addition, MacroChem will assume all clinical development, manufacturing and regulatory activities for pexiganan. MacroChem will require additional funding to fully develop the product.

About Pexiganan

Pexiganan is a 22-amino acid linear peptide. It is formulated as a cream and has a novel mechanism of action based on its ability to disrupt the integrity of bacterial cell membranes. It has antimicrobial activity against Gram positive (methycillin resistant staphylococcus aureus (MRSA)) and Gram negative organisms that commonly infect skin and soft tissue. It has a low potential for induction of resistance and no cross-resistance with existing therapeuti
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
(Date:10/28/2014)... 27, 2014)—Although oral hormonal therapy is known to ... hormone receptor–positive tumors, about one-half of patients fail ... by Columbia University Medical Center (CUMC) researchers has ... (the most common type of hormone therapy), which ... increased treatment adherence by 50 percent. , The ...
(Date:10/27/2014)... for informal caregiving of elderly people by friends and ... a year, according to a new RAND Corporation study. ... minimum wage would cost $221 billion, while replacing ... annually. , The study, published online by the ... the value of informal caregiving by making use of ...
(Date:10/27/2014)... adopt a new therapy by watching others use it, ... , New technology is like an influential colleague -- ... reminded every five to seven days , CHICAGO ... when they are persuaded to do so by an influential ... adopting innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 CALNOC, ... announced its annual CALNOC Performance Excellence Awards recognizing ... of reducing hospital acquired pressure ulcers, injuries from ... their commitment and dedication to nursing quality. , ... and affiliation. These hospitals have a long and ...
Breaking Medicine News(10 mins):Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 2Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 4
... Texas, Dec. 17 ULURU Inc. (Amex:,ULU) today ... Allowance from the,United States Patent and Trademark Office ... the underlying science behind the Company,s,nanoparticle aggregate technology; ... patent portfolio., Commenting on the issuance of ...
... 17 CSG/SportsCoatings,today announced a major deal ... and FabricAide(TM), to 25 high schools in,Virginia,s ... School District is the model for how ... steps towards minimizing prevalent,bacterial issues like staph ...
... acute and recurrent chronic pain are the leading causes of ... low as 2 percent when these soldiers are treated outside ... percent when troops and officers are treated and managed for ... for therapy, according to a new study from a Johns ...
... Researchers at Oregon Health & Science University have ... a study that suggests new strategies may be in ... The research is published in the current edition of ... The research focused on an important component of the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... Available Today, Offers Great ... and Now Even More Heart Benefits, HORSHAM, ... -- and then bulge -- from holiday parties ... availability of,NutriSystem Advanced, the company,s breakthrough weight-loss, health ...
Cached Medicine News:Health News:ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent 2Health News:Virginia School District Gets Proactive Against MRSA 2Health News:Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength 2Health News:OHSU research suggests new strategy for protecting aging Americans against infectious disease 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 3Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 4
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus sweatband....
Medicine Products: